

GCC Pharmaceutical Market Opportunity & Clinical Trials Outlook 2030

<https://marketpublishers.com/r/G41065482827EN.html>

Date: December 2024

Pages: 840

Price: US\$ 4,200.00 (Single User License)

ID: G41065482827EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

GCC Pharmaceutical Market Opportunity & Clinical Trials Outlook 2030 Report
Highlights:

GCC Pharmaceutical Market Opportunity: > US\$ 12 Billion By 2030

Saudi Arabia Domination GCC Pharmaceutical Market Landscape: > 50%

Branded & Imported Drug Dominate GCC Pharmaceutical Market Landscape

Number Of Drug Under Clinical Trials In GCC: > 250 Drugs

Clinical Trials Insight By Company, Country, Indication & Phase

Regulatory, Reimbursement and Insurance Insight By Country

Local & International Pharmaceutical Companies Insight

GCC Drug Registration Process

The Gulf Cooperation Council (GCC) pharmaceutical market stands as one of the most dynamic and rapidly expanding pharmaceutical sectors globally, with Saudi Arabia leading the region in market size and growth potential. The market's robust expansion is driven by multiple factors, including a growing population base, increasing life

expectancy, and rising prevalence of lifestyle-related diseases. For instance, Saudi Arabia's pharmaceutical market alone was valued at over US\$ 5 Billion, making it the largest in the region and attracting major global pharmaceutical companies like Pfizer and Novartis to establish regional headquarters.

Healthcare transformation programs across GCC countries have significantly impacted market growth. The UAE's Dubai Health Strategy and Saudi Arabia's Vision 2030 healthcare goals exemplify the massive government investments in healthcare infrastructure. These initiatives include the construction of healthcare cities, such as King Abdullah Medical City in Saudi Arabia and Dubai Healthcare City, which have become hubs for pharmaceutical distribution and medical excellence. Furthermore, the implementation of mandatory health insurance schemes, particularly in Dubai and Abu Dhabi, has dramatically increased access to prescription medications and boosted pharmaceuticals sales.

The market structure reflects a unique blend of import dependence and growing local manufacturing capabilities. While imported pharmaceuticals currently dominate, with European and American companies holding significant market share, local manufacturing is gaining momentum. Saudi Arabia's SPIMACO and UAE's Julphar serve as prime examples of successful local pharmaceutical manufacturers. These companies initially focused on generic medications but have gradually expanded their portfolios to include more complex products. For example, Julphar has successfully launched biosimilar products, including insulin, demonstrating the region's growing manufacturing sophistication.

Lifestyle related diseases have become a major driver of pharmaceutical demand in the GCC. The region shows some of the world's highest diabetes prevalence rates, with countries like Saudi Arabia and Kuwait reporting rates exceeding 15% of their adult population. This has created substantial markets for diabetes medications and related healthcare products. Similarly, the high prevalence of cardiovascular diseases has driven demand for medications like statins and antihypertensives, making these therapeutic categories among the largest in terms of sales volume.

Digital health integration has emerged as a significant trend shaping the market. UAE's Smart Dubai initiative includes digital health platforms that integrate electronic prescriptions and medication management systems. Kuwait's digital health transformation has introduced e-prescription services, reducing medication errors and improving pharmaceutical distribution efficiency. These digital innovations have created new opportunities for pharmaceutical companies to enhance their market presence and

service delivery.

The generics market represents a rapidly growing segment, driven by government initiatives to reduce healthcare costs. For example, Saudi Arabia's generic substitution policy has increased generic drug utilization from 30% to over 40% in recent years. Similar trends are observed in other GCC countries, where healthcare authorities actively promote generic alternatives to reduce pharmaceutical spending. Local manufacturers like Saudi Arabia's Jamjoom Pharma have successfully capitalized on this trend by focusing on high-quality generic alternatives to popular branded medications.

Looking ahead, the GCC pharmaceutical market faces both challenges and opportunities. While price control measures, such as Bahrain's unified drug pricing system, may impact profit margins, the growing demand for specialized medications presents significant opportunities. For instance, the oncology drugs segment has shown remarkable growth, driven by increasing cancer incidence rates and improved diagnosis capabilities. The biosimilars market also shows promise, with local manufacturers investing in biological drug production facilities, particularly in Saudi Arabia and the UAE.

The regulatory landscape continues to evolve, with the Gulf Central Committee for Drug Registration streamlining market access while maintaining quality standards. Recent examples include the accelerated registration pathways for innovative medications in Saudi Arabia and the UAE's fast-track registration system for vital drugs. These regulatory developments, combined with strong market fundamentals and government support, suggest continued growth and evolution of the GCC pharmaceutical market toward greater sophistication and self-sufficiency.

Contents

1. GCC PHARMACEUTICAL MARKET LANDSCAPE

- 1.1 Current Scenario
- 1.2 GCC Clinical Trials Landscape
- 1.3 GCC Drug Registration Process
 - 1.3.1 Decentralized & Centralized Drug Registration In GCC
 - 1.3.2 Drug Registration & Regulatory Bodies In GCC

2. GCC PHARMACEUTICAL MARKET DYNAMICS & OUTLOOK

- 2.1 Current Market Overview
- 2.2 Future Market Opportunities

3. SAUDI ARABIA PHARMACEUTICAL MARKET ANALYSIS

- 3.1 Overview
- 3.2 Regulatory Framework
- 3.3 Branded v/s Generic Drugs Availability
- 3.4 Reimbursement and Insurance Insight

4. SAUDI ARABIA CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 4.1 Phase I
- 4.2 Phase I/II
- 4.3 Phase II
- 4.4 Phase II/III
- 4.5 Phase III
- 4.6 Preregistration
- 4.7 Registered

5. SAUDI ARABIA MARKETED DRUGS CLINICAL INSIGHT BY COMPANY & INDICATION

6. UAE PHARMACEUTICAL MARKET ANALYSIS

- 6.1 Overview

- 6.2 Regulatory Framework
- 6.3 Branded v/s Generic Drugs Availability
- 6.4 Reimbursement and Insurance Insight

7. UNITED ARAB EMIRATES CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 7.1 Phase I
- 7.2 Phase I/II
- 7.3 Phase II
- 7.4 Phase II/III
- 7.5 Phase III
- 7.6 Preregistration
- 7.7 Registered
- 7.8 UAE Marketed Drugs Clinical insight By Company & Indication

8. QATAR PHARMACEUTICAL MARKET ANALYSIS

- 8.1 Overview
- 8.2 Regulatory Framework
- 8.3 Branded v/s Generic Drugs Availability
- 8.4 Reimbursement and Insurance Insight

9. QATAR CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 9.1 Phase II
- 9.2 Phase III
- 9.3 Preregistration
- 9.4 Registered

10. QATAR MARKETED DRUGS CLINICAL INSIGHT BY COMPANY & INDICATION

11. OMAN PHARMACEUTICAL MARKET ANALYSIS

- 11.1 Overview
- 11.2 Regulatory Framework
- 11.3 Branded v/s Generic Drugs Availability
- 11.4 Reimbursement & Insurance Insight

12. OMAN CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 12.1 Phase II
- 12.2 Phase II/III
- 12.3 Phase III
- 12.4 Preregistration
- 12.5 Registered

13. OMAN MARKETED DRUGS CLINICAL INSIGHT BY COMPANY & INDICATION

14. KUWAIT PHARMACEUTICAL MARKET ANALYSIS

- 14.1 Overview
- 14.2 Regulatory Framework
- 14.3 Branded v/s Generic Drugs Availability
- 14.4 Reimbursement and Insurance Insight

15. KUWAIT CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 15.1 Phase III
- 15.2 Preregistration
- 15.3 Registered

16. KUWAIT MARKETED DRUGS CLINICAL INSIGHT BY COMPANY & INDICATION

17. BAHRAIN PHARMACEUTICAL MARKET ANALYSIS

- 17.1 Overview
- 17.2 Regulatory Framework
- 17.3 Branded v/s Generic Drugs Availability
- 17.4 Reimbursement and Insurance Insight

18. BAHRAIN CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 18.1 Phase II
- 18.2 Preregistration
- 18.3 Registered

19. BAHRAIN MARKETED DRUGS CLINICAL INSIGHT BY COMPANY &

INDICATION

20. GCC PHARMACEUTICAL MARKET DRIVERS & CHALLENGES

20.1 Drivers & Opportunities

20.2 Challenges & Restraints

21. COMPETITIVE LANDSCAPE

21.1 Local Pharmaceutical Companies

21.1.1 Julphur Pharmaceuticals

21.1.2 SPIMACO Addwaeih

21.1.3 Qatar Life Pharma

21.1.4 Al Mojil Drug Company

21.1.5 Kuwait Saudi Pharmaceutical Company

21.1.6 YIACO Medical Company

21.1.7 Qatar Pharma

21.1.8 Saja Pharmaceuticals

21.1.9 Oman Pharmaceuticals

21.1.10 Taiba Pharmaceuticals

21.1.11 Gulf Biotech

21.1.12 Bahrain Pharma

21.1.13 Neopharma

21.1.14 Planet Pharmacies

21.1.15 Aljazeera Pharmaceutical Industries

21.1.16 Dallah Pharma

21.1.17 Tabuk Pharmaceuticals

21.1.18 CAD Middle-East Pharmaceutical Company

21.1.19 ACDIMA

21.1.20 AL-Mufid Pharmaceuticals

21.2 Multinational Companies

21.2.1 Novartis

21.2.2 Amgen

21.2.3 Eli Lilly

21.2.4 Merck

21.2.5 Pfizer

21.2.6 GlaxoSmithKline

21.2.7 Roche

21.2.8 Takeda Pharmaceuticals

21.2.9 Teva Pharmaceuticals

21.2.10 AstraZeneca

21.2.11 Genentech

21.2.12 Sanofi

Figure 1-1: GCC – Number Of Clinical Trials By Phase, 2024 Till 2030

Figure 1-2: Saudi Arabia – Number Of Clinical Trials By Phase, 2024 Till 2030

Figure 1-3: UAE – Number Of Clinical Trials By Phase, 2024 Till 2030

Figure 1-4: Oman – Number Of Clinical Trials By Phase, 2024 Till 2030

Figure 1-5: Qatar – Number Of Clinical Trials By Phase, 2024 Till 2030

Figure 1-6: Bahrain – Number Of Clinical Trials By Phase, 2024 Till 2030

Figure 2-1: GCC – Pharmaceutical Market Size, (US\$ Billion), 2023 - 2030

Figure 2-2: GCC – Pharmaceutical Market By Countries (%), 2023

Figure 2-3: GCC – Pharmaceutical Market By Countries (%), 2024

Figure 2-4: GCC – Pharmaceutical Market By Countries (%), 2030

Figure 3-1: Saudi Arabia - Drug Marketing Authorization Process

Figure 3-2: Saudi Arabia: Branded v/s Generic Drugs Market share (%), 2024

Figure 6-1: UAE - Drug Registration & Approval Process

Figure 6-2: UAE – Preference for Generic Drugs

Figure 8-1: Qatar - Drug Registration & Approval Process

Figure 11-1: Oman - Drug Registration Framework Features

Figure 14-1: Kuwait - Drug Registration Framework Features

Figure 17-1: Bahrain - Drug Registration & Approval Process

Figure 20-1: GCC Pharmaceutical Market – Drivers & Opportunities

Figure 20-2: GCC Pharmaceutical Market – Challenges & Restraints

Table 1-1: GCC - Regulatory Overview

I would like to order

Product name: GCC Pharmaceutical Market Opportunity & Clinical Trials Outlook 2030

Product link: <https://marketpublishers.com/r/G41065482827EN.html>

Price: US\$ 4,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G41065482827EN.html>